The findings arrive at a moment when irritable bowel syndrome has become one of the most common and frustrating diagnoses in gastroenterology. Classified among disorders of gut-brain interaction, IBS produces abdominal pain, bloating, and disturbed bowel habits in the absence of visible structural damage, and it resists most pharmacological treatments. That therapeutic vacuum has made acupuncture an increasingly popular option, and clinical trials have repeatedly reported that patients improve after a course of needling. But those trials also routinely show that patients receiving sham acupuncture improve nearly as much, raising a question that has shadowed complementary medicine research for decades: how much of the benefit is the needle, and how much is the mind?

To answer it, the researchers searched eight databases — PubMed, Embase, the Cochrane Library, Web of Science Core Collection, and four major Chinese databases including CNKI, Wanfang, VIP, and CBM — from their inception through July 4, 2026. They included only randomized controlled trials in which sham acupuncture served as a comparator in IBS patients, and they registered the protocol prospectively with PROSPERO under the identifier CRD420251035956. The primary outcome was the response rate, the proportion of patients who reported meaningful improvement, while secondary outcomes tracked changes in the IBS Symptom Severity Scale, the IBS Quality of Life scale, and abdominal pain intensity scores. Effect sizes were expressed as risk differences and pooled pre-to-post changes with 95 percent confidence intervals.

The headline numbers are striking. In patients who received sham acupuncture, the combined response rate was 0.38, meaning roughly 38 of every 100 patients treated with a placebo procedure reported feeling meaningfully better. On the IBS Symptom Severity Scale, scores fell by a pooled 60.08 points, with a confidence interval running from 70.62 down to 49.54 points of improvement. Quality of life scores rose by 8.23 points on average, and abdominal pain intensity dropped by 1.39 points on standard rating scales. None of these changes came from needles that penetrated classical acupoints in the way traditional theory prescribes; they emerged entirely from procedures intended to mimic acupuncture without its specific effects.

What does a 60-point drop on the symptom severity scale actually mean in clinical terms? The IBS-SSS is a 500-point instrument that captures pain intensity, pain frequency, bloating, satisfaction with bowel habits, and overall interference with daily life, and clinicians generally regard shifts of 50 points or more as clinically meaningful. By that yardstick, the placebo response documented in this analysis is not a statistical curiosity but a genuine therapeutic effect — one large enough that patients experience it as relief. Similarly, the 1.39-point reduction in pain intensity, measured on visual analog or numerical rating scales, represents a noticeable easing of the cramping and discomfort that define the condition.

Perhaps the most consequential part of the study, however, is not the headline effect size but the heterogeneity hiding beneath it. When the researchers stratified trials by their methodological and diagnostic characteristics, clear patterns emerged. Studies that used the Rome IV diagnostic criteria — the current international standard for defining functional gastrointestinal disorders — tended to report lower placebo responses than those relying on older Rome III or earlier criteria. Trials judged to be at low risk of bias also yielded smaller placebo effects, as did studies that defined treatment response according to the stringent criteria recommended by the U.S. Food and Drug Administration for IBS clinical trials. In other words, the more rigorous and modern the trial, the smaller the apparent power of the sham needle.

That pattern carries a lesson that extends well beyond acupuncture. Placebo responses are not fixed properties of a treatment; they are shaped by how trials are designed, how patients are selected, how outcomes are defined, and how much room subjective judgment has to wander. Older diagnostic criteria that swept in more heterogeneous patient populations, and looser definitions of what counts as a response, both inflate the apparent benefit of an inert procedure. The FDA’s patient-reported outcome requirements, which demand sustained improvement in abdominal pain and stool pattern rather than a fleeting global impression, are specifically engineered to filter out noise — and the analysis suggests they do exactly that, compressing the placebo response toward more conservative estimates.

The mechanisms behind a placebo response of this magnitude are likely multiple and overlapping. Ritualized, hands-on treatment delivers a dense bundle of contextual cues: a practitioner’s attention, the sensory experience of needling, the expectation of relief, and repeated clinical contact over weeks. IBS is, by definition, a disorder of gut-brain interaction, in which visceral sensitivity, stress physiology, and central pain processing are tightly entangled — making it precisely the kind of condition in which expectation and conditioning can plausibly modulate symptoms through real neurophysiological pathways. The gut’s enteric nervous system, its bidirectional communication with the brain via the vagus nerve and hypothalamic-pituitary-adrenal axis, and the endogenous opioid and cannabinoid systems all provide biological conduits through which psychological context can translate into altered gut sensation and motility.

For acupuncture researchers, the implications cut in two directions. On one hand, the substantial placebo response documented here means that any future trial of real acupuncture in IBS must be powered and designed to detect benefits that exceed this baseline — a demanding threshold, given that the sham arm already delivers clinically meaningful improvement to more than a third of patients. On the other hand, the finding does not automatically invalidate acupuncture as a therapy; it reframes the question. If part of acupuncture’s effect in IBS is a potent, ritual-mediated placebo response, some researchers argue that harnessing that response deliberately and ethically could itself be a legitimate clinical strategy, particularly for a condition with few effective drugs. The authors of the analysis note that several factors — diagnostic criteria, risk of bias, and response definitions — can notably influence the size of the placebo component, and that understanding these moderators is essential for interpreting both past and future trials.

For patients and clinicians, the study is a reminder that improvement after treatment is real even when the mechanism is expectation rather than needle stimulation — and that honest science can quantify that effect without dismissing the suffering it relieves. The 977 patients in these twelve trials who felt better after sham acupuncture were not imagining their symptoms fading; their brains and guts were genuinely recalibrating in response to context, ritual, and care. Disentangling how much of acupuncture’s benefit in IBS comes from specific needling effects and how much from this powerful contextual machinery will require trials that meet the highest methodological standards — Rome IV criteria, low risk of bias, and FDA-grade outcome definitions — and the new analysis provides the benchmark against which those trials can now be judged. In the meantime, it stands as one of the clearest quantitative demonstrations that in the contested territory of mind-body medicine, the placebo needle is anything but inert.

Subject of Research: Placebo response to sham acupuncture in patients with irritable bowel syndrome

Article Title: Placebo response of sham acupuncture in patients with irritable bowel syndrome: a systematic review and meta-analysis

Article References: Xiang, P., Wang, X., Li, B., Li, H., Zheng, W., Fan, X., Jiao, J., Wang, Y., Li, J., & She, Y. (2026). Placebo response of sham acupuncture in patients with irritable bowel syndrome: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05513-0

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05513-0

Keywords: irritable bowel syndrome, sham acupuncture, placebo response, meta-analysis, systematic review, randomized controlled trials, IBS-SSS, gut-brain interaction, Rome IV criteria, abdominal pain, complementary medicine, clinical trial methodology

Dr. Sharma’s impressive credentials include a distinguished tenure at the HonorHealth Research Institute, where he has been a pivotal force since 2017. His expertise encompasses research design, drug development, and clinical trial methodology, which have set new benchmarks in the field. Now, as Chief of Translational Research and Drug Discovery, Dr. Sharma will leverage his knowledge and leadership skills to spearhead initiatives that convert basic scientific discoveries into actionable cancer therapies, thereby bridging the gap between laboratory research and clinical application.

Under his guidance, a multidisciplinary team comprising scientists, researchers, chemists, and clinical personnel will work collaboratively to bring forth breakthrough therapies that harness cutting-edge science to improve the quality of life for cancer patients. This initiative reflects a broader trend in oncology aimed at integrating scientific discovery with patient care, fostering an environment where innovation thrives and patient outcomes are continually optimized.

Mark Slater, Ph.D., Vice President of Research at HonorHealth, expressed confidence in Dr. Sharma’s abilities, stating that he is uniquely qualified to lead this ambitious venture. Dr. Slater remarked on Dr. Sharma’s diverse skill set, noting his blend of scientific acumen, clinical expertise, and innovative thinking. As the institute seeks to elevate its research capabilities, Dr. Sharma’s role will be integral in developing educational programs and collaborations that will further enhance the institute’s reputation in the field.

This new leadership position is not only a testament to Dr. Sharma’s remarkable career but also aligns with HonorHealth Research Institute’s strategic partnership with Arizona State University’s School of Medicine and Advanced Medical Engineering. It signifies a groundbreaking initiative to combine academic research with clinical practice, allowing for a seamless transfer of knowledge and technology that amplifies the impact of research on patient care.

Dr. Sharma’s career is marked by his dedication to drug discovery and innovation. He has made substantial contributions to the field of cancer treatment by developing novel therapeutic approaches, particularly in the area of immunotherapy. His groundbreaking work has notably expanded beyond gastrointestinal cancers to address pressing health challenges such as COVID-19 and Alzheimer’s disease, illustrating his commitment to advancing medicine across multiple fronts.

As part of his expanded role, Dr. Sharma has also been appointed to the Virginia G. Piper Distinguished Chair in Innovative Cancer Research, previously held by renowned pancreatic cancer specialist Daniel D. Von Hoff, M.D. This position carries with it an endowment that will fund Dr. Sharma’s pioneering cancer research and clinical trials, ensuring that his initiatives will have the financial backing necessary to achieve meaningful, impactful results.

Dr. Sharma’s future endeavors will focus on harnessing the power of translational medicine, which seeks to expedite the application of laboratory findings to clinical environments. His vision for the Center for Translational Science emphasizes the importance of innovation in treatment modalities, aiming to develop therapies that not only address the disease’s biological underpinnings but also consider patient-centered approaches that improve overall well-being.

The breadth of Dr. Sharma’s experience includes key leadership roles at notable institutions like the Huntsman Cancer Institute and the Translational Genomics Research Institute (TGen), where he significantly advanced clinical research programs. His ability to foster collaborations with pharmaceutical companies enables him to bridge the gap between emerging scientific discoveries and tangible treatment options.

Among his notable achievements, Dr. Sharma has played a crucial role in developing targeted therapies such as ceritinib, pembrolizumab, and nivolumab, which have proven essential in the fight against various cancers, including lung cancer and melanoma. These therapeutic agents exemplify a new era in oncology where personalized medicine is paramount, allowing for tailored treatment strategies that maximize therapeutic efficacy while minimizing adverse effects.

His academic contributions are equally impressive, serving as a professor of medical oncology and mentoring numerous aspiring researchers and practitioners. Dr. Sharma’s profound impact on the field is not only evident in his clinical and research roles but also through his dedication to education and mentorship, nurturing the next generation of cancer researchers and clinicians who will continue the fight against this formidable disease.

Dr. Sharma’s commitment to advancing cancer research is rooted in a genuine desire to improve patient outcomes and quality of life. Throughout his career, he has maintained a clear focus on innovation and has consistently sought to explore new frontiers in treatment options deliberately. His appointment at the HonorHealth Research Institute signifies a renewed commitment to research excellence and patient care, ensuring that cutting-edge therapies are accessible to those in need.

As Dr. Sharma embarks on this new chapter at HonorHealth, the future looks promising for patients and researchers alike. His leadership will undoubtedly yield transformative results as the Center for Translational Science works diligently to pioneer breakthroughs in cancer care, ultimately striving to provide patients with access to the most advanced treatments available.

The HonorHealth Research Institute stands at the forefront of transformative cancer research, and with Dr. Sunil Sharma at the helm of the Center for Translational Science, the possibilities for innovative cancer therapies are limitless. This new era in cancer treatment is not only about scientific advancements but also about the unyielding spirit of compassion that Dr. Sharma embodies, aligning his journey with the broader goal of alleviating the burdens that cancer places on patients and their families.

With his extensive background, collaborative spirit, and unwavering commitment to scientific innovation, Dr. Sharma is primed to lead HonorHealth Research Institute into a future filled with promise and potential as they collectively tackle the complexities of cancer and work towards a world where cancer is no longer a death sentence, but a manageable condition.

By embracing the synergy of research, academic collaboration, and clinical expertise, HonorHealth Research Institute aims to usher in a new paradigm of care that prioritizes the patient experience while advancing the field of oncology.

Subject of Research: Translational research for cancer therapeutics
Article Title: HonorHealth Research Institute Welcomes Leading Expert in Anti-Cancer Drug Development as Director of New Center for Translational Science
News Publication Date: February 18, 2025
Web References: HonorHealth Research Institute
References: None
Image Credits: Credit: Courtesy of HonorHealth Research Institute
Keywords: Anti-cancer drugs, translational research, drug discovery, immunotherapy, cancer therapeutics, HonorHealth, Arizona State University